Studies conducted by Chen et al. [20], Chen et al. [21], and Wang et al. [22] showed that a low pre-treatment serum ALB level independently predicted worse overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) in HCC patients undergoing curative surgical resection. The gene discussed is ALB; the disease is hepatocellular carcinoma.